APVO:NSD-Aptevo Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.42

Change

+0.02 (+0.45)%

Market Cap

USD 0.02B

Volume

0.10M

Avg Analyst Target

USD 16.50 (+273.30%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


APVO Stock Forecast & Price:
Based on the Aptevo Therapeutics Inc stock forecasts from 1 analysts, the average analyst target price for Aptevo Therapeutics Inc is USD 16.50 over the next 12 months. Aptevo Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aptevo Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, Aptevo Therapeutics Inc’s stock price was USD 4.42. Aptevo Therapeutics Inc’s stock price has changed by +3.03% over the past week, +8.60% over the past month and -73.10% over the last year.

About Aptevo Therapeutics Inc (APVO:NSD)

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+2.36 (+0.81%)

USD74.93B 24.21 16.33
REGN Regeneron Pharmaceuticals Inc

+4.81 (+0.77%)

USD69.21B 12.88 9.34
MRNA Moderna Inc

-0.63 (-0.37%)

USD68.17B 5.42 4.08
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+1.76 (+1.11%)

USD38.32B 3.09 2.08
SGEN Seagen Inc

-3.90 (-2.24%)

USD32.10B 55.02 -46.75
RPRX Royalty Pharma Plc

+0.50 (+1.14%)

USD29.54B 42.84 20.93
ALNY Alnylam Pharmaceuticals Inc

+4.46 (+1.94%)

USD27.16B N/A -34.32
GMAB Genmab AS

-0.69 (-1.83%)

USD23.25B 72.63 6.37
ARGX argenx NV ADR

+2.77 (+0.74%)

USD20.75B N/A -20.02

ETFs Containing APVO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -43.84% 38% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -43.84% 38% F 26% F
Trailing 12 Months  
Capital Gain -74.00% 23% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -74.00% 23% F 15% F
Trailing 5 Years  
Capital Gain 163.10% 84% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 163.10% 84% B 85% B
Average Annual (5 Year Horizon)  
Capital Gain 826.57% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 826.57% 98% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 2,217.59% 2% F 1% F
Risk Adjusted Return 37.27% 79% C+ 70% C-
Market Capitalization 0.02B 12% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 40.80 20% F 23% F
Price/Book Ratio 19.27 6% F 5% F
Price / Cash Flow Ratio -1.02 26% F 56% F
EV/EBITDA 0.35 24% F 52% F
Management Effectiveness  
Return on Equity -1,281.95% 2% F 1% F
Return on Invested Capital -73.49% 33% F 14% F
Return on Assets -22.08% 60% D- 19% F
Debt to Equity Ratio 304.85% 6% F 7% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.85 71% C- 67% D+
Short Percent 1.68% 70% C- 63% D
Beta 5.89 0% N/A 0% N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector